- Cognoa and EVERSANA form a partnership that will enable prescription, dispensation, and reimbursement of Cognoa’s behavioral health products.
- Cognoa is developing digital medicine solutions to change the standard of care in pediatric behavioral health to improve the lifelong outcomes for children.
- Cognoa selected EVERSANA, a fully integrated and independent commercial services platform, to develop and manage a go-to-market strategy that ensures comprehensive market
Read More
prescription digital therapeutic
Modis Therapeutics Raises $30M for Developing Medicines for Patients with Rare Genetic Diseases
Modis Therapeutics, Inc., a company developing medicines for patients with rare genetic diseases has raised $30 million in Series A funding led by F-Prime Capital Partners and OrbiMed. Joshua Grass, former F-Prime Entrepreneur-in-Residence and head of Corporate Development at BioMarin Pharmaceutical, has joined as President and Chief Executive Officer. Founding investor Aceras Life Sciences, LLC and new investor Osage University Partners also participated in the financing.Founded in 2016, Modis
Read More
Magellan Health Launches First FDA-Approved Prescription Digital Therapeutic
Magellan Health has announced the launch of reSET therapy, a pilot initiative using the first-ever FDA cleared prescription digital therapeutic from PEAR Therapeutics to improve outcomes for individuals struggling with Substance Use Disorders (SUD) and other related conditions.With the current challenges in our nation related to substance use, the evidence-based, non-drug treatment option presented with this approach is an opportunity to offer a practical solution to meet these complex needs and
Read More
